ABL1 and acute lymphoblastic leukemia: The outcome of patients with BCR-ABL positive ALL has improved dramatically with the use of tyrosine-kinase inhibitors (TKIs) with overall survival more than 50% at 1 to 4 years.13–15 Although most patients did not undergo SCT, our study showed a MS of 23 months in this patient population using imatinib with either HCVAD or CALGB regimen.